SkinMedica

company

About

SkinMedica is focused on developing, acquiring, and commercializing products that improve the appearance of skin.

  • 51 - 100

Details

Last Funding Type
Series E
Last Funding Money Raised
$11M
Industries
Biotechnology,Medical,Medical Device
Founded date
Jan 1, 1999
Number Of Employee
51 - 100
Operating Status
Active

SkinMedica is focused on developing, acquiring, and commercializing products that improve the appearance of skin. SkinMedica markets and sells to physicians, with a focus on aesthetics, both prescription and non-prescription skin care products. The company's full line of aesthetic skin care products includes the revolutionary TNS Essential Serum® and hallmark TNS Recovery Complex®. The formulations in SkinMedica’s clinical skin care collection enhance skin appearance, reduce signs of aging, and provide other skin care benefits. SkinMedica's primary prescription product, VANIQA® (eflornithine hydrochloride) Cream 13.9%, is the only FDA-approved prescription product for the reduction of unwanted facial hair in women. Colorescience Pro’s dermatologist recommended, high-performance cosmetics are formulated to remedy and camouflage specific skin concerns and protect skin from damaging effects of the sun and environment. Colorescience Pro’s luxury aesthetic makeup line is sold in the physician and medical spa channels.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
$56M
SkinMedica has raised a total of $56M in funding over 2 rounds. Their latest funding was raised on Apr 12, 2006 from a Series E round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Apr 12, 2006 Series E $11M 1 Detail
Apr 6, 2005 Series E $15M 1 Detail
Jul 14, 2004 Series D $30M 1 Perseus-Soros Biopharmaceutical Fund Detail

Investors

Number of Lead Investors
Number of Investors
1
1
SkinMedica is funded by 1 investors. Perseus-Soros Biopharmaceutical Fund are the most recent investors.
Investor Name Lead Investor Funding Round
Perseus-Soros Biopharmaceutical Fund Series E